What we've seen with that, since it is over 10 years, is that we went from being number six in the world in per capita use to number two, and I don't think we want to be number one—that's the U.S.
What we've seen with that 200% increase is a very similar doubling of unintended overdose deaths, a doubling of access for treatment services around opiates in particular, in a treatment system that I would suggest was already very much under duress or under stress to accommodate its existing clients.
We as a government, if I can say that, pay often for this. We pay to dispense it—often it was covered by formulary—and we pay in terms of the treatment modality and some of the lost productivity and mortality. This strategy, while it will require some financial investment, will undoubtedly decrease the entire cost load across the system because of the current situation.